Abstract
The clinical efficacy of using «protected» aminopenicillins (amoxicillin/clavulanate, amoxicillin/sulbactam) and the 3rd generation cephalosporins in the treatment of mild community-acquired pneumonia in patients older than 60 years in hospital has been evaluated. Analyzed 71 case histories. The assessment was carried out on the basis of a comprehensive analysis of clinical, laboratory and radiological data. A comparative analysis of the clinical efficacy and safety of the antibiotic regimens under study demonstrated the obvious advantage of using «protected» aminopenicillins over the existing practice of treating non-severe community-acquired pneumonia in patients of older age groups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
